These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 17714028)

  • 1. Advances in the development of hormonal modulators for the treatment of benign prostatic hyperplasia.
    Tiwari A
    Expert Opin Investig Drugs; 2007 Sep; 16(9):1425-39. PubMed ID: 17714028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benign prostatic hyperplasia: an insight into current investigational medical therapies.
    Tiwari A; Krishna NS; Nanda K; Chugh A
    Expert Opin Investig Drugs; 2005 Nov; 14(11):1359-72. PubMed ID: 16255676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol).
    Maggi M; Crescioli C; Morelli A; Colli E; Adorini L
    J Endocrinol Invest; 2006; 29(7):665-74. PubMed ID: 16957418
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
    Tarter TH; Vaughan ED
    Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha adrenergic antagonists for the treatment of symptomatic BPH.
    Lepor H
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):151-5. PubMed ID: 2469658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha-Adrenoceptor antagonists in the treatment of benign prostate hyperplasia.
    Thiyagarajan M
    Pharmacology; 2002 Jul; 65(3):119-28. PubMed ID: 12037374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of combination medical therapy in benign prostatic hyperplasia.
    Greco KA; McVary KT
    Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia.
    Pinto F; Racioppi M; Sacco E; Totaro A; Brescia A; Volpe A; Gardi M; Bassi PF
    Arch Ital Urol Androl; 2009 Mar; 81(1):1-8. PubMed ID: 19499750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Drugs for the treatment of benign prostatic hypertrophy].
    Caprino L
    Minerva Urol Nefrol; 2000 Jun; 52(2):87-92. PubMed ID: 11085067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terazosin. A pharmacoeconomic evaluation of its use in benign prostatic hyperplasia.
    Plosker GL; Goa KL
    Pharmacoeconomics; 1997 Feb; 11(2):184-97. PubMed ID: 10165827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
    Silva J; Silva CM; Cruz F
    Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microwave thermotherapy for benign prostatic hyperplasia.
    Hoffman RM; Monga M; Elliot SP; Macdonald R; Wilt TJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004135. PubMed ID: 17943811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
    Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Nandy I; Morrill BB; Gagnier RP; Montorsi F;
    Eur Urol; 2010 Jan; 57(1):123-31. PubMed ID: 19825505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign prostatic hyperplasia - progress in pathophysiology and management.
    Dobrek Ł; Thor PJ
    Pol Merkur Lekarski; 2015 Nov; 39(233):263-70. PubMed ID: 26637089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.
    O'Leary MP; Roehrborn C; Andriole G; Nickel C; Boyle P; Höfner K
    BJU Int; 2003 Aug; 92(3):262-6. PubMed ID: 12887480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in the design and discovery of drugs for the treatment of prostatic hyperplasia.
    Kumar R; Malla P; Kumar M
    Expert Opin Drug Discov; 2013 Aug; 8(8):1013-27. PubMed ID: 23662859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silodosin: a selective alpha1A-adrenergic receptor antagonist for the treatment of benign prostatic hyperplasia.
    Schilit S; Benzeroual KE
    Clin Ther; 2009 Nov; 31(11):2489-502. PubMed ID: 20109995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia.
    Gupta K; Yezdani M; Sotelo T; Aragon-Ching JB
    Expert Opin Investig Drugs; 2015; 24(8):1059-73. PubMed ID: 25982036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the development of new drugs for treatment of benign prostatic hyperplasia.
    Kulig K; Malawska B
    Curr Med Chem; 2006; 13(28):3395-416. PubMed ID: 17168713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.